Association of large joint involvement at the start of biological disease‐modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study

Aim To investigate the association of large joint involvement (LJI) with disease activity and drug retention in patients with rheumatoid arthritis (RA) who started receiving a biological disease‐modifying antirheumatic drug or Janus kinase inhibitor. Methods Patients with RA from a Japanese multicen...

Full description

Saved in:
Bibliographic Details
Published in:International journal of rheumatic diseases 2024-03, Vol.27 (3), p.e15097-n/a
Main Authors: Shirasugi, Iku, Onishi, Akira, Nishimura, Keisuke, Yamamoto, Wataru, Murakami, Kosaku, Onizawa, Hideo, Maeda, Yuichi, Ebina, Kosuke, Son, Yonsu, Amuro, Hideki, Katayama, Masaki, Hara, Ryota, Nagai, Koji, Hiramatsu, Yuri, Hashimoto, Motomu, Okano, Tadashi, Maeda, Toshihisa, Hayashi, Shinya, Sendo, Sho, Jinno, Sadao, Yamamoto, Yuzuru, Yamada, Hirotaka, Ueda, Yo, Saegusa, Jun
Format: Article
Language:English
Subjects:
Ankle
biological disease‐modifying antirheumatic drugs
Citrulline
Elbow
Enzyme inhibitors
Hip
Interleukin 6
Janus kinase
Janus kinase inhibitor
Joint diseases
large joint involvement
Patients
Retention
Rheumatoid arthritis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim To investigate the association of large joint involvement (LJI) with disease activity and drug retention in patients with rheumatoid arthritis (RA) who started receiving a biological disease‐modifying antirheumatic drug or Janus kinase inhibitor. Methods Patients with RA from a Japanese multicenter observational registry were enrolled. Our definition of large joints included the shoulder, elbow, hip, knee, and ankle joints. Linear mixed‐effects models were used to examine changes in the clinical disease activity index (CDAI) score at Week 24 as the primary outcome, and drug retention rates were compared between patients with and without LJI using Cox proportional hazards models. We examined the potential effect modifications of changes in the CDAI by baseline characteristics. Results Overall, 2507 treatment courses from 1721 patients were included (LJI, 1744; no LJI, 763). Although LJI was associated with significantly higher changes in CDAI from baseline at Week 24 (difference in change in CDAI: −5.84 [−6.65 to −5.03], p 
ISSN:1756-1841
1756-185X
DOI:10.1111/1756-185X.15097